C. Pazoles

发表

Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells.

E. Garrett-Mayer, S. Glück, Ying Zhu, 2009 .

NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): A randomized Phase 1/2, open-label, controlled study.

H. Gerstein, C. Pazoles, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract C238: Nov‐002, a cellular redox modulator, enhances the antitumor effect of adoptively transferred T cells in a murine melanoma model

Min Xu, A. Montero, M. Salem, 2009 .

Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic.

D. Townsend, K. Tew, Y. Manevich, 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.